Subscribe Become an Author Log In

BiopharmaTrend.com

Covering emerging technologies, innovations, and companies

Small Molecules


Converging Trends Brings Organic Electrochemistry To The Front Line Of Drug Discovery

   by Alfred Ajami    3208
Converging Trends Brings Organic Electrochemistry To The Front Line Of Drug Discovery

In a case of "back to the future", chemists at Scripps collaborating with instrument engineers at IKA have unveiled a powerful tool for electrifying chemistry to achieve complex reactions. The ElectraSyn is expected to change approaches to 3D-molecules, late-stage derivatization, and focused library construction, while promoting environmentally conscious chemistry. The teaser graphic here is from Ref. 5 in the text that follows.

Novartis Explores Virtual Reality Tools In Drug Discovery R&D

   by BiopharmaTrend    2257
Novartis Explores Virtual Reality Tools In Drug Discovery R&D

Virtual reality (VR) has been a hot topic in game industry lately, but now it finds its way to biopharmaceutical research. Novartis is exploring opportunities to leverage this new technology for the benefit of early-stage small molecule drug discovery research. Using VR researchers at Novartis are able to visualize protein targets and small molecules and explore interactions between them in a visual three-dimensional mode.

Takeda Partners With Numerate To Use Artificial Intelligence For Drug Discovery

   by BiopharmaTrend    7854
Takeda Partners With Numerate To Use Artificial Intelligence For Drug Discovery

A multi-year research agreement has just been announced between Takeda Pharmaceuticals (TSE: 4502) and an Artificial Intelligence (AI)-driven computational drug design company Numerate, Inc. Under this contract, Numerate will have to come up with new clinical candidates in the Takeda’s core therapeutic areas: oncology, gastroenterology, and central nervous system disorders.

Unveiling Hidden Drug Targets

   by Andrii Buvailo    4046
Unveiling Hidden Drug Targets

Scientists estimated that the human genome encodes above 20,000 different proteins in our body. However, available public databases contain records of known ligands for only about 10% of all proteins. Expanding the map of “druggable” proteins increases the chances of running into novel small molecule drugs.

A recent study, published in Cell, opens doors for unveiling novel drug targets and even reconsidering some of the known protein targets, previously tagged “undruggable”.